Roche Molecular Dx Revenue Slides 3 Percent as Applied Science Surges 10 Percent Over Past Nine Months | GenomeWeb
NEW YORK (GenomeWeb News) — Roche reported today that total receipts for its molecular diagnostics segment declined 3 percent in the first three quarters of 2007, compared with the same period one year ago, but overall revenue for the entire Diagnostics business rose 5 percent year over year.
 
Diagnostics sales overall rose to CHF 6.8 billion ($5.7 billion) while Molecular Diagnostics declined to CHF 856 million. However, excluding industrial reagents, sales in Molecular Diagnostics were up 3 percent.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.